Polymer Capital Management (HK)’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.23M Buy
190,739
+90,276
+90% +$1.48M 0.21% 83
2026
Q2
$1.96M Buy
+100,463
New +$1.82M 0.1% 91

Other funds holding MLTX

Polymer Capital Management (HK)'s MLTX Position: Q3 2026 in Review

Polymer Capital Management (HK) increased its MoonLake Immunotherapeutics (MLTX) stake by 90% in Q3 2026, buying an estimated $1.48M and bringing the position to 190,739 shares worth $2.23M. The position accounts for 0.21% of the portfolio, ranked #83.

Polymer Capital Management (HK) first reported a position in MLTX in Q2 2026 and has held it in 2 quarters since. 170 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • Polymer Capital Management (HK) held 190,739 shares of MoonLake Immunotherapeutics worth $2.23M as of Q3 2026.
  • Polymer Capital Management (HK) bought 90,276 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $1.48M.
  • MoonLake Immunotherapeutics made up 0.21% of Polymer Capital Management (HK)'s portfolio in Q3 2026, its #83 holding.
  • Polymer Capital Management (HK) first reported a position in MoonLake Immunotherapeutics in Q2 2026 and has held it in 2 quarters since.
  • 170 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Polymer Capital Management (HK)'s 13F filing for Q3 2026, filed 13 Nov 2026.